<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OFLOXACIN</span><br/>(o-flox'a-cin)<br/><span class="topboxtradename">Floxin, </span><span class="topboxtradename">Floxin Otic, </span><span class="topboxtradename">Ocuflox<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification"> antibiotic, quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 300 mg, 400 mg tablets; 200 mg, 400 mg injection; 0.3% ophthalmic solution; 0.3% otic solution</p>
<h1><a name="action">Actions</a></h1>
<p>A fluoroquinolone antibiotic with a broad spectrum of activity against gram-positive and gram-negative aerobic and anaerobic
         bacteria. Inhibits DNA gyrase, an enzyme necessary for bacterial DNA replication and some aspects of its transcription, repair,
         recombination, and transposition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Most effective against gram-negative organisms including <i>Citrobacter diversus, C. freundii, Enterobacter cloacae, E. aerogenes, Escherichia coli, Klebsiella</i> species, <i>Morganella morganii, Proteus</i> species, <i>Salmonella</i> species, <i>Shigella</i> species, and <i>Yersinia enterocolitica</i>. More potent against <i>Serratia</i> species than is norfloxacin, and it is equipotent against <i>Providencia</i> species; less active against <i>Pseudomonas aeruginosa</i> but more potent against <i>Xanthomonas maltophilia</i> than is ciprofloxacin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>
<i>Chlamydia trachomatis</i> infection, uncomplicated gonorrhea, prostatitis, respiratory tract infections, skin and skin structure infections, urinary
         tract infections due to susceptible bacteria, superficial ocular infections, pelvic inflammatory disease. Otic: otitis externa,
         otitis media with perforated tympanic membranes.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>EENT infections, <i>Helicobacter pylori</i> infections, <i>Salmonella</i> gastroenteritis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ofloxacin or other quinolone antibacterial agents; tendon pain; sunlight (UV) exposure; viral infection;
         pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal disease; patients with a history of epilepsy, psychosis, or increased intracranial pressure, cerebrovascular disease,
         CNS disorders such as seizures, epilepsy, myasthenia gravis; GI disease, colitis, dehydration; syphilis. Safety and effectiveness
         in children and adolescents 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg for 1 dose<br/><br/><span class="indicationtitle">Urinary Tract, Respiratory Tract, and Skin and Skin Structure Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200400 mg q12h times 710 d <span class="rdroute">IV</span> 400 mg q12h times 7 d<br/><br/><span class="indicationtitle">Prostatitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg b.i.d. times 6 wk <span class="rdroute">IV</span> 300 mg q12h times 10 d, then switch to <span class="rdroute">PO</span> for 6 wk<br/><br/><span class="indicationtitle">Superficial Ocular Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> Instill 12 drops q24h for first 2d, then q.i.d. for up to 5 additional d<br/><br/><span class="indicationtitle">Otitis Media with Perforation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Otic</span> 10 drops (0.5 mL) q12h for 14 d<br/><span class="rdage">Child:</span> <span class="rdroute">Otic</span>
<i><img src="../images/special/greaterorequal.gif"/>1 y,</i> 5 drops (0.25 mL) q12h for 14 d<br/><br/><span class="indicationtitle">Otitis Externa</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Otic</span>  10 drops (0.5 mL) q12h for 7 d<br/><span class="rdage">Child:</span> <span class="rdroute">Otic</span>
<i>6 mo13 y,</i> 5 drops (0.25 mL) q12h for 7 d <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give with meals.</li>
<li>Avoid administering mineral supplements or vitamins with iron or zinc within 2 h of drug.</li>
<li>Do not give antacids with magnesium, aluminum, or sucralfate within 4 h before or 2 h after drug.</li>
</ul><span class="adminroutetype">Instillation</span><br/><ul>
<li>Do <small>NOT</small> allow tip of dropper for ocular preparation to contact any surface.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Withdraw the required dose from a 10 mL (40 mg/mL) or 20 mL (20 mg/mL) vial and add to 100 mL D5W, NS, D5/NS or other compatible
                  solution. Final concentration may range from 0.4 mg/mL to 4 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give a single dose over at least 60 min. Avoid rapid infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b> Amphotericin B, cholesteryl sulfate complex,</b>
<b>cefepime,</b>
<b>doxorubicin liposome.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness, insomnia,</span> hallucinations. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, GI discomfort. <span class="typehead">Urogenital:</span> Pruritus, pain, irritation, burning, vaginitis, vaginal discharge, dysmenorrhea, menorrhagia, dysuria, urinary frequency. <span class="typehead">Skin:</span> Pruritus, rash. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Ofloxacin absorption decreased when it is administered with <span class="classification">magnesium-</span> or <span class="classification">aluminum-containing antacids</span>. Other <span class="classification">cations</span>, including <b>calcium,</b>
<b>iron,</b> and <b>zinc,</b> also appear to interfere with ofloxacin absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 9098% absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Distributes to most tissues; 50% crosses into CSF with inflamed meninges; 2032% protein bound; crosses placenta;
      distributed into breast milk. <span class="typehead">Metabolism:</span> Slightly metabolized in liver. <span class="typehead">Elimination:</span> 7298% excreted in urine within 48 h. <span class="typehead">Half-Life:</span> 57.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Do C&amp;S tests prior to initial dose. Treatment may be implemented pending results.</li>
<li>Determine history of hypersensitivity reactions to quinolones or other drugs before therapy is started.</li>
<li>Withhold ofloxacin and notify physician at first sign of a skin rash or other allergic reaction.</li>
<li>Monitor for seizures, especially in patients with known or suspected CNS disorders. Discontinue ofloxacin and notify physician
            immediately if seizure occurs.
         </li>
<li>Assess for signs and symptoms of superinfection (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drink fluids liberally unless contraindicated.</li>
<li>Be aware that dizziness or light-headedness may occur; use appropriate caution.</li>
<li>Avoid excessive sunlight or artificial ultraviolet light because of the possibility of phototoxicity.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>